Exhibit No.	Description
10.47†	Amendment to Distribution and Manufacturing Services Agreement with Sanquin Blood Supply Foundation, dated as of September 24, 2007 (32) (Exhibit 10.2)
10.48	Strategic Supply Agreement, dated as of April 3, 2008, between the Company and Plasma Centers of America, LLC (33) (Exhibit 10.2)
10.49	Intermediate Supply Agreement, dated as of April 9, 2008, between the Company and Biotest, AG (34) (Exhibit 10.2)
10.50	Lease Agreement with 730 Stockton Drive Associates, L.P. dated March 14, 2008. (35) (Exhibit 10.1)
10.51††	Letter Agreement with Michel de Rosen dated March 30, 2008 (36) (Exhibit 10.1)
10.52††	Letter Agreement between the Company and Robert Pietrusko dated January 9, 2009 (28) (Exhibit 10.1)
14	Code of Conduct and Ethics. (14)(Exhibit 14)
21*	List of Subsidiaries.
23*	Consent of KPMG LLP, Independent Registered Public Accounting Firm.
24*	Power of Attorney (included on signature page).
31.1*	Certification by Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification by Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

^{*} Filed herewith.

- †† Compensation plans and arrangements for executives and others.
- (1) Filed as an Exhibit to Registrant's Form 10-Q for the quarter ended June 30, 2000.
- (2) Filed as an Exhibit to the Company's Current Report on Form 8-K filed with the Commission on November 14, 2008.
- (3) Filed as an Exhibit to the Company's Current Report on Form 8-K filed with the Commission on July 18, 2008.
- (4) Filed as an Exhibit to Registrant's Form 10-Q for the quarter ended September 30, 2003.
- (5) Filed as an Exhibit to Registrant's Form 10-Q for the quarter ended March 31, 1999.
- (6) Filed as an Exhibit to the Current Report on Form 8-K filed with the Commission on July 18, 2008 by Lev Pharmaceuticals, Inc.
- (7) Filed as an Exhibit to Registrant's Form 10-K for the year ended December 31, 1999.
- (8) Filed as an Exhibit to Form 10-KSB filed by Lev Pharmaceuticals, Inc. on March 31, 2005.
- (9) Filed as an Exhibit to Registrant's Form 10-Q for the quarter ended March 31, 2001.
- (10) Filed as an Exhibit to Registrant's Form 10-K for the year ended December 31, 2001.
- (11) Filed as an Exhibit to Registrant's Form 10-Q for the quarter ended June 30, 2002.
- (12) Filed as an Annex to Registrant's Proxy Statement filed with the Commission on March 27, 2003.
- (13) Filed as an Exhibit to Registrant's Form 10-Q for the quarter ended June 30, 2003.
- (14) Filed as an Exhibit to Registrant's Current Report on Form 8-K filed with the Commission on April 11, 2008.
- (15) Filed as an Exhibit to the Company's Current Report on Form 8-K/A filed with the Commission on November 24, 2004.
- (16) Filed as an Exhibit to the Company's Current Report on Form 8-K filed with the Commission on November 29, 2004.
- (17) Filed as an Exhibit to the Company's Current Report on Form 8-K filed with the Commission on February 15, 2005.
- (18) Filed as an Annex to Registrant's Proxy Statement filed with the Commission on April 8, 2002.
- (19) Filed as an Exhibit to Registrant's Form 10-K for the year ended December 31, 2004.
- (20) Filed as an Exhibit to Registrant's Form 10-Q for the quarter ended June 30, 2005.
- (21) Filed as an Exhibit to Registrant's Form 10-K for the year ended December 31, 2005.
- (22) Filed as an Exhibit to Registrant's Form 10-Q for the quarter ended June 30, 2006.
- (23) Filed as an Exhibit to Registrant's Form 10-K for the year ended December 31, 2008.
- (24) Field as Annex to Registrant's Proxy Statement filed with the Commission on April 11, 2008.
- (25) Filed as an Exhibit to the Company's Registration Statement on Form S-3 (333-141411) filed with the Commission on March 19, 2007.

[†] Portions of this exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.